Merck KGaA - MKGAF Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$143.30
▲ +1.25 (0.88%)

This chart shows the closing price for MKGAF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Merck KGaA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MKGAF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MKGAF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Merck KGaA in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $143.30.

This chart shows the closing price for MKGAF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Buy

The current consensus among 1 polled investment analysts is to buy (strong buy) stock in Merck KGaA.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2024

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/19/2024The Goldman Sachs GroupUpgradeStrong-Buy
(Data available from 12/23/2019 forward)

News Sentiment Rating

-0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/27/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/26/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/26/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/25/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
10/24/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/23/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/23/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Positive

  • No very positive mentions tracked during this time.
Merck KGaA logo
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.
Read More

Today's Range

Now: $143.30
Low: $140.58
High: $145.18

50 Day Range

MA: $156.52
Low: $142.05
High: $180.40

52 Week Range

Now: $143.30
Low: $140.58
High: $200.56

Volume

3,666 shs

Average Volume

534 shs

Market Capitalization

$18.52 billion

P/E Ratio

21.88

Dividend Yield

N/A

Beta

0.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Merck KGaA?

The following Wall Street analysts have issued reports on Merck KGaA in the last year: The Goldman Sachs Group, Inc..
View the latest analyst ratings for MKGAF.

What is the current price target for Merck KGaA?

0 Wall Street analysts have set twelve-month price targets for Merck KGaA in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Merck KGaA in the next year.
View the latest price targets for MKGAF.

What is the current consensus analyst rating for Merck KGaA?

Merck KGaA currently has 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for MKGAF.

What other companies compete with Merck KGaA?

Other companies that are similar to Merck KGaA include GSK, Takeda Pharmaceutical, UCB, UCB and Alnylam Pharmaceuticals. Learn More about companies similar to Merck KGaA.

How do I contact Merck KGaA's investor relations team?

Merck KGaA's physical mailing address is Frankfurter Strasse 250, Darmstadt 2M, 64293. The company's listed phone number is 496151720 and its investor relations email address is [email protected]. The official website for Merck KGaA is www.merckgroup.com. Learn More about contacing Merck KGaA investor relations.